Please use this identifier to cite or link to this item:
|Title:||Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review.|
Proto-Oncogene Proteins p21(ras)
|Abstract:||From 2008-2013, the European indication for panitumumab required that patients' tumor KRAS exon 2 mutation status was known prior to starting treatment. To evaluate physician awareness of panitumumab prescribing information and how physicians prescribe panitumumab in patients with metastatic colorectal cancer (mCRC), two European multi-country, cross-sectional, observational studies were initiated in 2012: a physician survey and a medical records review. The first two out of three planned rounds for each study are reported.|
|Appears in Collections:||Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.